A new enzyme immunoassay specific for blastomycosis.

Area of Science:

• Medical Mycology
• Immunodiagnostics
• Infectious Diseases

Background:

• Blastomycosis diagnosis relies on sensitive and specific methods.
• Current serological tests for blastomycosis may lack optimal sensitivity or specificity.
• Cross-reactivity with other fungal infections is a challenge in serodiagnosis.

Purpose of the Study:

• To develop and evaluate a highly specific enzyme immunoassay (EIA) for the serodiagnosis of blastomycosis.
• To assess the sensitivity and specificity of the novel EIA compared to existing methods.
• To determine if the EIA avoids cross-reactions with other endemic mycoses and controls for rheumatoid factors.

Main Methods:

• Development of a blastomycosis-specific enzyme immunoassay (EIA).
• Testing of sera from eight active blastomycosis cases, including one with acquired immunodeficiency syndrome (AIDS).
• Evaluation of cross-reactivity using sera from patients with histoplasmosis, coccidioidomycosis, and healthy individuals. Control for rheumatoid factors.

Main Results:

• Seven of eight early blastomycosis sera were reactive by the specific EIA.
• The EIA showed no cross-reactivity with sera from histoplasmosis, coccidioidomycosis, or healthy controls.
• Conventional EIAs using commercial antigens showed cross-reactivity, unlike the developed blastomycosis-specific EIA.

Conclusions:

• The developed blastomycosis-specific EIA demonstrates high sensitivity and specificity for serodiagnosis.
• This EIA avoids cross-reactions seen with conventional methods, improving diagnostic accuracy.
• The assay is a promising tool for the reliable detection of blastomycosis infections.